+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.

Age: 18Years +All GendersPhase 3
259 locations
S

Actively Recruiting

Researchers are evaluating the effects of vericiguat compared to placebo in children and adolescents with heart failure caused by left ventricular systolic dysfunction. The study aims to determine if vericiguat can better reduce levels of a heart failure marker called NT-proBNP over 16 weeks. This research is a Phase 23 clinical trial assessing efficacy, safety, and pharmacokinetics in pediatric participants. Participants receive either vericiguat or placebo daily by mouth in tablet or suspension form for 52 weeks during the Base Period. After completing this phase, eligible participants can join an optional open-label Extension Period where they receive vericiguat daily. The study incorporates a previously separate extension arm, allowing long-term follow-up of up to approximately 8 years. Throughout the study, participants will have their NT-proBNP levels measured and monitored at various time points, including baseline, Week 16, Week 52, and during the Extension Period. Researchers will also track adverse events and reasons for stopping the study drug. Additional assessments include heart failure events, pharmacokinetic measurements, and safety evaluations. The total study duration can extend up to 8 years for some participants.

Age: 29Days - 17YearsAll GendersPhase 2Phase 3
111 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of saruparib AZD5305 combined with camizestrant compared to physicians choice of CDK46 inhibitors plus endocrine therapy in patients with BRCA1, BRCA2, or PALB2 mutated, hormone receptor-positive, HER2-negative advanced breast cancer. This phase III study aims to determine which treatment better controls disease progression in this specific patient population. Participants will be randomly assigned to one of four treatment groups saruparib plus camizestrant physicians choice CDK46 inhibitor plus endocrine therapy physicians choice CDK46 inhibitor plus camizestrant or saruparib plus physicians choice endocrine therapy. Treatments are given orally or by injection as appropriate and will continue until the disease progresses, unacceptable side effects occur, or participants choose to stop treatment. During the study, participants will have regular assessments to evaluate disease progression, survival, response to treatment, and quality of life. Researchers will monitor drug levels in the blood and collect tissue samples to support diagnostic development. The study may last up to several years, with ongoing safety and efficacy evaluations to understand the impact of these treatments on advanced breast cancer.

Age: 18Years +All GendersPhase 3
306 locations